Search

Displaying results 3771 - 3780 of 7186 in total
  1. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Although the mechanisms of resistance to covalent BTK inhibitors have not been fully elucidated, it appears that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK … [A256758,A256773,L44863] However, other mutations may confer resistance to non-covalent BTK inhibitors such as pirtobrutinib.

  2. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.

  3. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    Compared to its homolog, [DB09061], CBDV is shortened by two methyl (CH2) groups on its side chain. … It is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis, or marijuana [A32584].

  4. Drug

    Human papillomavirus type 11 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10300
    ApprovedInvestigational

    The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

  5. Drug

    Human papillomavirus type 16 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10301
    ApprovedInvestigational

    The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

  6. Drug

    Human papillomavirus type 18 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10302
    ApprovedInvestigational

    The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

  7. Drug

    Oxazepam

    go.drugbank.com/drugs/DB00842
    Approved

    as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. … Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous

  8. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    Pipotiazine has actions similar to those of other phenothiazines. … Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics.

  9. Drug

    Parathyroid hormone

    go.drugbank.com/drugs/DB05829
    ApprovedInvestigational

    Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA). … Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence

  10. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    Up to now (July 2013), the results of this study have not yet been published. … investigational drug, it is being studied in a non-blinded prospective case study in the United States looking at patients who have been diagnosed with small fiber peripheral neuropathy between the ages of 18 to

    Synonyms: N-(4-aminobutyl)guanidine